Megan C Lindley1, Jenny Jeyarajah1, David Yankey1, C Robinette Curtis1, Lauri E Markowitz2, Shannon Stokley1. 1. a Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta , Georgia. 2. b Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta , Georgia.
Abstract
BACKGROUND/ OBJECTIVE: Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Previous research suggests some differences between male and female adolescents in correlates of vaccine receipt and reasons for non-vaccination; few studies examine both sexes together. This analysis assessed knowledge and attitudes related to HPV disease and vaccination, intention to vaccinate, and reasons for delayed vaccination or non-vaccination among parents of boys and girls 13-17 y old in 50 states, the District of Columbia, and selected local areas. METHODS: National Immunization Survey-Teen 2013 data were analyzed and gender differences examined. RESULTS: In this sample, adolescent boys were more likely than girls to be unvaccinated and less likely to have completed the HPV vaccination series (p < 0.005 for both). Parents of girls were more likely than parents of boys to report a provider recommendation for HPV vaccination (65.0% vs. 42.1%). Only 29% of girls' parents reported a provider recommendation to begin vaccination by 11-12 y old. Among unvaccinated teens, parental intention to vaccinate in the next 12 months did not differ by sex, but reasons for vaccination or non-vaccination did. Many parents do not know the recommended number of HPV doses. CONCLUSIONS: Gender differences in provider vaccination recommendations and reasons for vaccination might partially explain differential HPV uptake by male and female adolescents. Clinicians should offer strong recommendations for HPV vaccination at 11-12 y old for both girls and boys. To reduce missed opportunities, HPV vaccination should be presented in the context of, and given concurrently with, other routinely administered vaccines.
BACKGROUND/ OBJECTIVE:Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. Previous research suggests some differences between male and female adolescents in correlates of vaccine receipt and reasons for non-vaccination; few studies examine both sexes together. This analysis assessed knowledge and attitudes related to HPV disease and vaccination, intention to vaccinate, and reasons for delayed vaccination or non-vaccination among parents of boys and girls 13-17 y old in 50 states, the District of Columbia, and selected local areas. METHODS: National Immunization Survey-Teen 2013 data were analyzed and gender differences examined. RESULTS: In this sample, adolescent boys were more likely than girls to be unvaccinated and less likely to have completed the HPV vaccination series (p < 0.005 for both). Parents of girls were more likely than parents of boys to report a provider recommendation for HPV vaccination (65.0% vs. 42.1%). Only 29% of girls' parents reported a provider recommendation to begin vaccination by 11-12 y old. Among unvaccinated teens, parental intention to vaccinate in the next 12 months did not differ by sex, but reasons for vaccination or non-vaccination did. Many parents do not know the recommended number of HPV doses. CONCLUSIONS: Gender differences in provider vaccination recommendations and reasons for vaccination might partially explain differential HPV uptake by male and female adolescents. Clinicians should offer strong recommendations for HPV vaccination at 11-12 y old for both girls and boys. To reduce missed opportunities, HPV vaccination should be presented in the context of, and given concurrently with, other routinely administered vaccines.
Entities:
Keywords:
adolescent health; human papillomavirus; immunizations; prevention; vaccination coverage
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Jessica A Kahn; Susan L Rosenthal; Abbigail M Tissot; David I Bernstein; Caitlin Wetzel; Gregory D Zimet Journal: Ambul Pediatr Date: 2007 Sep-Oct
Authors: Alex Vorsters; Paolo Bonanni; Helena C Maltezou; Joanne Yarwood; Noel T Brewer; F Xavier Bosch; Sharon Hanley; Ross Cameron; Eduardo L Franco; Marc Arbyn; Nubia Muñoz; Mira Kojouharova; Jade Pattyn; Marc Baay; Emilie Karafillakis; Pierre Van Damme Journal: Papillomavirus Res Date: 2019-08-30
Authors: Alexandria C Caldwell; Christi A Madden; David M Thompson; M Connor Garbe; James R Roberts; Robert M Jacobson; Paul M Darden Journal: Hum Vaccin Immunother Date: 2020-10-19 Impact factor: 3.452
Authors: Tom T Shimabukuro; John R Su; Paige L Marquez; Adamma Mba-Jonas; Jorge E Arana; Maria V Cano Journal: Pediatrics Date: 2019-11-18 Impact factor: 7.124
Authors: James L Klosky; Melissa M Hudson; Yanjun Chen; James A Connelly; Karen Wasilewski-Masker; Can-Lan Sun; Liton Francisco; Laura Gustafson; Kathryn M Russell; Gina Sabbatini; Jessica S Flynn; Jocelyn M York; Anna R Giuliano; Leslie L Robison; F Lennie Wong; Smita Bhatia; Wendy Landier Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Abigail M Schnaith; Erica M Evans; Caleb Vogt; Andrea M Tinsay; Thomas E Schmidt; Katelyn M Tessier; Britt K Erickson Journal: Vaccine Date: 2018-05-31 Impact factor: 3.641
Authors: Ellen M Daley; Cheryl A Vamos; Erika L Thompson; Gregory D Zimet; Zeev Rosberger; Laura Merrell; Nolan S Kline Journal: Papillomavirus Res Date: 2017-04-23